港股異動 | 復宏漢霖(2696.HK)高開5.54% 抗S1全人源單克隆中和抗體HLX70的臨牀試驗申請獲FDA批准
格隆匯10月8日丨復宏漢霖(2696.HK)高開5.54%,報48.6港元,最新總市值264億港元。復宏漢霖近日發公告稱,新冠病毒中和抗體HLX70針對新冠病毒肺炎、新冠病毒引起的急性呼吸窘迫綜合徵(ARDS)或多重器官衰竭等適應症的新藥臨牀試驗申請,獲美國食品藥品監督管理局(FDA)批准。HLX70於中國境內(不包括港澳台地區)處於臨牀前研究階段。截至公告日,於全球範圍內尚無新冠肺炎抗體藥物獲批上市。野村曾發報告稱,將公司2020至2022年的收入預測分別上調至9.35億、25.57億及38.39億元人民幣,維持“買入”評級,目標價由52.4港元上調至76.7港元。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.